Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
SHSE:688505 株式レポート
Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd マネジメント Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtdの CEO はDa Jun Zhaoで、 May2023年に任命され、 の在任期間は 1.5年です。 の年間総報酬はCN¥ 1.88Mで、 89.9%給与と10.1%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の1.51%を直接所有しており、その価値はCN¥ 112.82M 。経営陣と取締役会の平均在任期間はそれぞれ1.5年と1.5年です。
主要情報 CEO給与比率 89.9% CEO在任期間 1.5yrs CEOの所有権 1.5% 経営陣の平均在職期間 1.5yrs 取締役会の平均在任期間 1.5yrs
経営陣の近況
すべての更新を表示
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 26, 2024 Sep 30
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Announces First Patient Enrolled in Phase II Clinical Trial in the United States of Hemoporfin for Injection for the Treatment of Port Wine Birthmark Sep 23
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Announces First Patient Enrolled in Phase III Clinical Trial of FDA018 Antibody Drug Conjugate for Injection for the Treatment of Triple Negative Breast Cancer Aug 26
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. announces Annual dividend, payable on October 10, 2024 Aug 13
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Announces First Patient in Phase I Clinical Trial of Fz-Ad005 Antibody Drug Conjugate for Injection Jul 24 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. to Report Q2, 2024 Results on Aug 15, 2024
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Application Dec 18
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Investigational New Drug Nov 15
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Acceptance Notice Issued by the National Medical Products Administration of the PRC Oct 21
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Announces First Patient Enrolled in Phase I Clinical Trial of FZ-AD004 Antibody Drug Conjugate for the Treatment of Advanced Solid Tumors Aug 10
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Acceptance Notice for the Investigational New Drug Application Jan 19
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Announces Indicative Announcement-First Patient Enrolled in Phase I Clinical Trial of FDA022 Antibody Drug Conjugate for Injection for the Treatment of Advanced Solid Tumors Jan 18
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Acceptance Notice Issue by the National Medical Products Administration of the PRC Nov 18
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. to Report Q3, 2022 Results on Oct 27, 2022 Oct 18 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Announces Supplemental Announcement Related to Earnings Guidance for the Six Months Ended 30 June 2022
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2022 Aug 16
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Received the Acceptance Notice of the Quality and Efficacy Consistency Evaluation of Generic Drugs for Chemical Injection Jul 20
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Approves Final Dividend for the Year Ended 31 December 2021, Payable on or Before 26 August 2022 Jun 30
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives the Acceptance Notice Issued by the National Medical Products Administration of the Prc Jun 09
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. to Report Q1, 2022 Results on Apr 29, 2022 Apr 20 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Proposes Final Dividend for the Year Ended 31 December 2021, Payable on 26 August 2022
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021 Mar 05
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 29, 2020 Oct 17
CEO報酬分析 Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd の収益と比較して、Da Jun Zhao の報酬はどのように変化したか? 日付 総報酬 給与 会社業績 Sep 30 2024 n/a n/a CN¥105m
Jun 30 2024 n/a n/a CN¥111m
Mar 31 2024 n/a n/a CN¥102m
Dec 31 2023 CN¥2m CN¥2m CN¥109m
Sep 30 2023 n/a n/a CN¥191m
Jun 30 2023 n/a n/a CN¥242m
Mar 31 2023 n/a n/a CN¥142m
Dec 31 2022 CN¥3m CN¥2m CN¥138m
Sep 30 2022 n/a n/a CN¥132m
Jun 30 2022 n/a n/a CN¥112m
Mar 31 2022 n/a n/a CN¥213m
Dec 31 2021 CN¥5m CN¥2m CN¥213m
Sep 30 2021 n/a n/a CN¥198m
Jun 30 2021 n/a n/a CN¥201m
Mar 31 2021 n/a n/a CN¥188m
Dec 31 2020 CN¥3m CN¥1m CN¥165m
Sep 30 2020 n/a n/a CN¥191m
Jun 30 2020 n/a n/a CN¥165m
Mar 31 2020 n/a n/a CN¥204m
Dec 31 2019 CN¥3m CN¥1m CN¥227m
Sep 30 2019 n/a n/a CN¥151m
Jun 30 2019 n/a n/a CN¥151m
Mar 31 2019 n/a n/a CN¥91m
Dec 31 2018 CN¥2m CN¥1m CN¥112m
Sep 30 2018 n/a n/a CN¥95m
Jun 30 2018 n/a n/a CN¥78m
Mar 31 2018 n/a n/a CN¥77m
Dec 31 2017 CN¥1m CN¥1m CN¥75m
報酬と市場: Da Junの 総報酬 ($USD 260.34K ) は、 CN市場 ($USD 133.70K ) の同規模の企業の平均を上回っています。
報酬と収益: Da Junの報酬は、過去 1 年間の会社の業績と一致しています。
CEO(最高経営責任者 Mr. Da Jun Zhao has been an Executive Director at Taizhou SPH Pharmaceutical Co., Ltd. since January 2002. Mr. Zhao Co-Founded Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. in November 1996 and ser ... Show more
リーダーシップ・チーム 名称 ポジション 在職期間 報酬 所有権 Co-Founder 1.5yrs CN¥1.88m 1.51% CN¥ 112.8m CFO, Deputy GM 14.3yrs CN¥1.18m 0.20% CN¥ 14.7m Co-Founder & Deputy GM 28yrs CN¥2.22m 0.87% CN¥ 65.1m Core Technical Personnel no data データなし 0.11% CN¥ 8.5m Deputy General Manager 1.5yrs データなし 0.064% CN¥ 4.8m Deputy General Manager 1.5yrs データなし 0.018% CN¥ 1.3m Deputy General Manager 1.5yrs データなし 0.020% CN¥ 1.5m
もっと見る
経験豊富な経営陣: 688505の経営陣は 経験豊富 とはみなされません ( 1.5年の平均在職年数)。これは新しいチームを示唆しています。
取締役 名称 ポジション 在職期間 報酬 所有権 Co-Founder 22.8yrs CN¥1.88m 1.51% CN¥ 112.8m CFO, Deputy GM 1.5yrs CN¥1.18m 0.20% CN¥ 14.7m Non-Executive Director 11.5yrs データなし データなし Supervisor 1.5yrs データなし データなし Non Executive Director 12.4yrs データなし データなし Independent Chairman of Supervisory Board 7.4yrs データなし データなし Independent Non-Executive Director 1.5yrs CN¥116.67k データなし Independent Non-Executive Director 1.5yrs データなし データなし Independent Non-Executive Director 1.5yrs CN¥116.67k データなし Employee Representative Supervisor 1.5yrs データなし 0.0038% CN¥ 281.5k
もっと見る
経験豊富なボード: 688505の 取締役会 は 経験豊富 ではない ( 1.5年の平均在任期間) ため、新しい取締役会が必要であると考えられます。
Simply Wall St™ Simply Wall Street Pty Ltd Level 7, 320 Pitt Street, Sydney Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":false,"variant":{"name":"disabled","enabled":false},"flagsReady":false,"flagsError":null}